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Abstract
Introduction: Systemic sclerosis (SSc) is an autoimmune disease characterized by chronic inflammation, vascular
injury and excessive fibrosis. CD163 is a scavenger receptor which affects inflammatory response and may
contribute to connective tissue remodelling. It has recently been demonstrated that CD163 can bind and neutralize
the TNF-like weak inducer of apoptosis (TWEAK), a multifunctional cytokine which regulates inflammation,
angiogenesis and tissue remodelling. We aimed to investigate the relationships between serum levels of soluble
CD163 (sCD163) and soluble TWEAK (sTWEAK) in relation to disease manifestations in SSc patients.
Methods: This study included 89 patients with SSc who had not received immunosuppressive drugs or steroids for
at least 6 months and 48 age- and sex-matched healthy controls (HC) from four European centres. Serum
concentrations of sTWEAK and sCD163 were measured using commercially available ELISA kits.
Results: The mean serum concentrations of sTWEAK were comparable between SSc patients (mean +/- SD:
270 +/- 171 pg/mL) and HC (294 +/- 147pg/mL, P >0.05). Concentration of sCD163 and sCD163/sTWEAK ratio were
significantly greater in SSc patients (984 +/- 420 ng/mL and 4837 +/- 3103, respectively) as compared to HC
(823 +/- 331 ng/mL and 3115 +/- 1346 respectively, P <0.05 for both). High sCD163 levels and a high sCD163/
sTWEAK ratio (defined as > mean +2SD of HC) were both associated with a lower risk of digital ulcers in SSc
patients (OR, 95%CI: 0.09; 0.01, 0.71, and 0.17; 0.06, 0.51, respectively). Accordingly, patients without digital ulcers
had a significantly higher sCD163 concentration and sCD163/sTWEAK ratio as compared to SSc patients with digital
ulcers (P <0.01 for both) and HC (P <0.05 for both). A high sCD163/sTWEAK ratio, but not high sCD163 levels, was
associated with greater skin involvement.
Conclusions: The results of our study indicate that CD163-TWEAK interactions might play a role in the
pathogenesis of SSc and that CD163 may protect against the development of digital ulcers in SSc. Further studies
are required to reveal whether targeting of the CD163-TWEAK pathway might be a potential strategy for treating
vascular disease and/or skin fibrosis in SSc.
Introduction
Systemic sclerosis (SSc, scleroderma) is a chronic, auto-
immune disease, which affects skin, the lungs, heart, gas-
trointestinal tract and the kidneys. Excessive production
of extracellular matrix by activated fibroblasts and wide-
spread vascular injury are believed to play a key role in
the pathogenesis of SSc. In addition, inflammatory infil-
trates consisting mainly of mononuclear cells are found
in the skin and affected organs, in particular in the early
stage of the disease [1,2].
CD163 is a member of the scavenger receptor cysteine-
rich (SRCR) family, which is expressed exclusively in
monocytes/macrophages and takes part in the uptake of
circulating haptoglobin-haemoglobin complexes [3,4].
Shedding of membrane CD163 through a proteolytic pro-
cess produces soluble CD163 molecule (sCD163), which
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can be detected in body fluids [5-7]. Both membrane
bound and soluble CD163 (sCD163) exert strong
anti-inflammatory effects [8]. Uptake of haptoglobin-
haemoglobin complexes by CD163-expressing macro-
phages leads to increase in production of interleukin-10
and expression of haeme oxygenase -1 [9]. Soluble CD163
can directly inhibit T cells proliferation [10,11]. Expression
of CD163 on tissue macrophages increases during
the resolution phase of acute inflammatory response [8].
Similarly, increase in plasma levels of sCD163 and expres-
sion of CD163 on monocytes have been associated with
lack of prolonged airway inflammation after allergen chal-
lenge in asthmatic patients [12]. Moreover, expression of
CD163 increases during the wound healing phase, indicat-
ing a possible role of CD163 in the regulation of connec-
tive tissue remodelling [13,14].
Recently, it has been shown that CD163 can specifically
bind and neutralize TNF-like weak inducer of apoptosis
(TWEAK), a newly identified pleiotropic cytokine belong-
ing to the TNF-a superfamily of cytokines [15]. TWEAK
is involved in the regulation of inflammation, angiogenesis
and tissue repair and remodelling [16,17]. Interacting with
its specific receptor, fibroblast growth factor-inducible 14
(Fn14) (TWEAKR), TWEAK activates NF-kB and mito-
gen-activated protein (MAP) kinase pathways and induces
production of pro-inflammatory mediators, including
interleukin-6, interleukin-8, monocyte chemotactic pro-
tein-1 and several metalloproteinases by different cell
types, including macrophages, fibroblasts, and endothelial
cells [17-21]. TWEAK also stimulates endothelial cell
migration, proliferation and survival and cooperates with
other pro-angiogenic factors such as vascular endothelial
growth factor (VEGF) and fibroblast growth factor (FGF)
in the regulation of development of new blood vessels
[16]. Moreover, TWEAK can directly activate fibroblasts
[19-21].
As mentioned above, binding of TWEAK to CD163
neutralizes TWEAK and in this way inhibits its function
[15]. Moreover, it has recently been shown that CD163-
expressing monocytes/macrophages are able to bind and
internalize exogenous TWEAK [22]. It has also been
shown that sCD163/sTWEAK ratio in peripheral blood
is a more sensitive biomarker of subclinical athero-
sclerosis than sCD163 or sTWEAK alone, indicating
that interactions between TWEAK and CD163 might
play an important role in vivo [22]. Since both CD163
and TWEAK have been implicated in the regulation of
fibroblast function, their interactions might also be of
importance for connective tissue remodelling.
Only a few papers have reported on the evaluation of
serum levels of sCD163 or sTWEAK in SSc. However,
none have addressed the issue of the mutual relationship
between sCD163 and sTWEAK in SSc [23-25]. Taking
into account molecular interaction between TWEAK
and CD163 molecules, in the present study we evaluated
concentration of both proteins in a sample of 89 SSc
patients and 48 healthy controls.
Patients and methods
Eighty-nine patients and appropriate healthy controls
(HC) from four clinical centres were enrolled. All patients
fulfilled the American College of Rheumatology (ACR)
classification criteria for SSc and/or Medsger and LeRoy
criteria for early SSc [26,27]. Only patients who had not
received immunosuppressive therapies or steroids for at
least 6 months before the study were considered eligible.
In addition, all patients with known coronary artery dis-
ease, clinical manifestations of atherosclerosis, such as
stroke or peripheral obliterative arterial disease, as well as
those with symptoms of infection were excluded from the
study. Patients were classified as having diffuse cutaneous
SSc (dSSc) or limited cutaneous SSc (lSSc) as defined by
LeRoy and Medsger [28]. Patients’ assessment included
evaluation of duration of Raynaud’s phenomenon and
duration of the disease defined from the first non-
Raynaud’s symptom attributable to SSc. In order to better
understand the relationship between disease duration and
changes in expression of investigated molecules, patients
were divided into those with short- and long-term disease.
In agreement with previous studies, patients were consid-
ered as having short-term disease if disease duration was
not longer than 3 years in dSSc or 5 years in lSSc mea-
sured from the first non-Raynaud symptom [29-31].
Accordingly, patients with dSSc in whom disease lasted
longer than 3 years and patients with lSSc in whom dis-
ease lasted longer than 5 years were considered as having
long-term disease.
The extent of skin involvement was assessed using the
modified Rodnan skin score (mRSS), as described else-
where [32]. The presence of scleroderma interstitial lung
disease (ILD) was defined based on the typical findings
in high resolution computed tomography (HRCT) of the
lungs. Pulmonary function tests were used for assess-
ment of the severity of lung involvement and included
measurements of forced vital capacity (FVC) and diffu-
sion capacity of the lungs for carbon monoxide (DLCO).
Pulmonary artery systolic pressure (PASP) was calcu-
lated based on the tricuspid regurgitation velocity on
Doppler echocardiography. The presence of pulmonary
hypertension (PH) was defined as PASP higher than
45 mmHg, which was shown to have 95% specificity ver-
sus right heart catheterization, which is considered a
gold standard for diagnosis of PH [33]. Scleroderma
renal crisis was defined as new renal insufficiency with
or without arterial hypertension, which could not be
explained other than by SSc.
As in previous studies, digital ulcers (DU) were
defined as a painful area of loss of tissue located on the
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volar surface of the fingertips or around the nail distal
to the proximal interphalangeal digital crease, present at
the time of blood collection [34].
The presence of antinuclear antibodies (ANA) and
anticentromere antibodies (ACA) was assessed by indir-
ect immunofluorescence and the presence of anti-topoi-
somerase antibodies (anti-topo I) was evaluated using
ELISA. Erythrocyte sedimentation rate (ESR) was used
as a laboratory parameter of activity of systemic
inflammation.
The control group consisted of 48 age- and sex-
matched healthy subjects without evidence of any dis-
ease including atherosclerosis or infection (Table 1).
The study protocol was approved by the bioethics
committee at the Medical University of Bialystok, and
informed consent was obtained from all patients.
Measurements of sCD163 and sTWEAK in the sera
Peripheral blood was collected from cubical vein after
the patient had fasted for at least 10 hours; the blood
was allowed to coagulate for 30 minutes. Subsequently,
samples were centrifuged, and sera were collected and
stored at -80°C until measurements were taken [35].
Serum sCD163 and sTWEAK levels were measured
using commercially available ELISA kits (sCD163 from
R&D Systems, Inc. Minneapolis, MN, USA; sTWEAK
from Bender Medsystems, Vienna, Austria) according to
the protocol provided by the manufacturer.
Statistical analysis
For between-group comparisons, the Kruskal-Wallis test,
the Mann-Whitney U-test and Fisher’s test were used,
as appropriate. Correlations between continuous values
were evaluated using Spearman’s rank test. Potential
relationships between individual parameters were
assessed using univariate and multivariate regression
analysis. All parameters with P <0.1 in univariate regres-
sion analysis were included in multivariate regression.
For all other tests P <0.05 was considered significant.
Values are given as mean and SD unless stated other-
wise. Values in SSc patients higher than the mean + 2
SD of the control group were considered high. To assess
the association between high concentrations of soluble
proteins, or high sCD163/sTWEAK ratio and the pre-
sence of DU, the odds ratio (OR) with 95% CI was
calculated.
Results
Clinical characteristics of SSc patients
Of the patients, 20 (23%) had dSSc and the remaining
69 (77%) had lSSc. HRCT of the lungs revealed ILD in
55 patients (62%). PH was found in 4 out of 81 (5%)
patients in whom the results of echocardiography were
available. Thirty-eight patients (43%) had DU at the
time of the study. None of the patients had scleroderma
renal crisis. ANA, anti-topo I antibodies and ACA were
found in 84 (94%), 35 (39%) and 33 (37%) patients,
respectively. Arterial hypertension of unknown cause
Table 1 Clinical characteristics of the patients with systemic sclerosis and the control group.
Parametera SSc patients
(n = 89)
Controls
(n = 48)
Female/male ratio 80/9 42/6c
Age, years 57.23 ± 12.31 53.71 ± 14.38c
Disease duration, yearsb 10.65 ± 9.00
Duration of Raynaud’s phenomenon, years (data available for 54 patients only) 9.59 ± 8.45
dSSc/lSSc, number of patients 20/69
ANA-positive, n (%) patients 84 (94.38)
Anti-topo I-positive, n (%) patients 35 (39.33)
ACA-positive, n (%) patients 33 (37.08)
ILD by HRCT/radiograph, n (%) patients 55 (61.78)
Pulmonary hypertension, n (%) patients (data available for 81 patients only) 4 (4.94)
Digital ulcers, n (%) patients 38 (42.70)
Scleroderma renal crisis, n (%) patients 0
Arterial hypertension, n (%) patients 8 (9.00) 0
CCBs, n (%) patients
Pentoxyphylline, n (%) patients
ACEIs, n (%) patients
Sildenafil, n (%) patients
NSAIDs, n (%) patients
27 (30.34)
33 (37.08)
12 (13.48)
4 (4.49)
13 (14.61)
0
0
0
0
0
Values are given as mean ± SD unless stated otherwise. aData available for 89 patients unless stated otherwise; bcalculated from the time of the first non-
Raynaud’s symptom attributable to SSc; cstatistically non-significant (P >0.05). ACA, anticentromere antibodies; ACEIs, angiotensin-converting enzyme inhibitors;
ANA, antinuclear antibodies; CCBs, calcium channel blockers; dSSc, diffuse systemic sclerosis; HRCT, high resolution computed tomography; lSSc, limited systemic
sclerosis; ILD, scleroderma interstitial lung disease; NSAIDs, non-steroidal anti-inflammatory drugs. Detailed definitions of particular organ involvement are given
in the methods section.
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(considered essential) was found in 8 SSc patients (9%)
and none of the control subjects. When enrolled into
the study, 27 SSc patients (30%) were being treated with
calcium channel blockers (CCBs), 33 (37%) with pentox-
yphylline, 12 (14%) with angiotensin-converting enzyme
inhibitors (ACEIs), 4 (5%) with sildenafil and 13 (15%)
with non-steroidal anti-inflammatory drugs (NSAIDs).
Detailed clinical characteristics of the SSc patients are
presented in Table 1.
Serum concentrations of sCD163 and sTWEAK
The mean concentration of sCD163 in patients with SSc
(mean ± SD 984 ± 420 ng/mL, range 302 to 2,275 ng/mL)
was significantly higher than in HC (823 ± 331 ng/mL,
range 329 to 1,659 ng/mL; P = 0.023) (Figure 1). High
sCD163 concentration, defined as greater than the mean +
2 SD of the value in HC (1,485 ng/mL), was found in 13
SSc patients (15%). Comparison of those 13 SSc patients
with high sCD163 concentration with the remaining 76
SSc patients revealed that patients with high serum
sCD163 were less likely to have DU compared with those
with normal sCD163 concentration (Table 2). Indeed, DU
were present in only one out of thirteen (8%) SSc patients
with high serum sCD163 concentration compared with 37
out of 76 (48%) SSc patients with normal sCD163 levels
(OR 0.09, 95% CI 0.01, 0.71; P <0.05). Accordingly, the
mean concentration of sCD163 in patients without DU
(1,119 ± 439 ng/mL) was significantly higher than in
patients with DU (802 ± 317 ng/mL, P = 0.002) (Figure 1).
Moreover, the mean concentration of sCD163 in the
former subgroup of SSc patients was significantly higher
than in HC (P = 0.0008), whereas the mean concentration
of sCD163 in SSc patients with DU did not differ signifi-
cantly from the control group (P >0.05) (Figure 1).
No significant association or correlation was found
between serum sCD163 concentration and any other
clinical or laboratory factor (Tables 2 and 3). There were
no significant differences in serum concentration of
sCD163 between SSc patients receiving different thera-
pies or between those with and without arterial hyperten-
sion (data not shown), nor any other significant
associations between different treatments or the presence
of arterial hypertension and sCD163 levels (Table 2).
The mean serum concentrations of sTWEAK were com-
parable between patients with SSc (270 ± 171 pg/mL,
range 56 to 1,135 pg/mL) and HC (294 ± 147 pg/mL,
range 132 to 1,015 pg/mL, P >0.05) (Figure 2). In SSc
patients sTWEAK showed a weak inverse correlation with
duration of SSc (R = -0.32 P = 0.002) (Table 3). Accord-
ingly, concentration of sTWEAK was significantly greater
in 33 patients with short-term SSc (334 ± 222 pg/mL) as
compared to the remaining 56 SSc patients with longer
disease duration (232 ± 120 pg/mL, P = 0.01) (Figure 2).
The mean concentration of sTWEAK in SSc patients with
short-term disease did not differ significantly from the
control group (P = 0.7) while sTWEAK levels in SSc
patients with longer disease duration was significantly
diminished compared with HC (P = 0.02). However, in
multivariate regression analysis including disease duration
and other clinical parameters of the disease, no significant
Figure 1 Serum concentration of sCD163 in patients with systemic sclerosis (SSc) and healthy controls. Concentration of sCD163 in the sera of
all SSc patients (SSc), SSc patients without digital ulcers (DU-), SSc patients with digital ulcers (DU+) and healthy controls. Closed circles represent
values in individual subjects, bars represent the mean values of the groups, and horizontal lines the appropriate SDs. NS, not significant.
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association between sTWEAK and disease duration was
found (data not shown).
High sTWEAK concentration (above the mean + 2SD
of the control group, which was 588 pg/mL) was found
in two patients only (Figure 2). Because of the small
number of SSc patients with high sTWEAK levels, no
reliable statistical comparisons between SSc patients
with high or normal sTWEAK concentration were per-
formed. There were no further significant associations
between sTWEAK and clinical or laboratory parameters
of the disease in SSc patients (Tables 2 and 3). There
were no significant differences in serum concentration
of sTWEAK between SSc patients receiving different
therapies or between those with and without arterial
hypertension (data not shown). Serum concentrations of
sCD163 and sTWEAK did not correlate with each other
either in patients with SSc (R = -0.05, P >0.05) or in the
whole group (R = 0.1, P >0.05).
sCD163/sTWEAK ratio and clinical and laboratory
parameters of disease
The mean sCD163/sTWEAK ratio was significantly higher
in patients with SSc (4,837 ± 3,103, range 660 to 14,440)
compared with HC (3,115 ± 1,346, range 980 to 6,160;
P <0.001) (Figure 3). High sCD163/sTWEAK ratio (greater
than the mean + 2SD of HC, which was 5,807) was found
in 29 (33%) SSc patients. Comparison of those 29 SSc
patients with high sCD163/sTWEAK ratio to the remain-
ing 60 SSc patients showed that high sCD163/sTWEAK
ratio was associated with greater skin involvement as indi-
cated by higher mRSS (Table 2). The diffuse form of the
disease was twice as frequent (35%) in patients with high
sCD163/sTWEAK ratio as in SSc patients with normal
sCD163/sTWEAK ratio (18%), but the difference was of
borderline significance (P = 0.055) (Table 2). Moreover,
patients with high sCD163/sTWEAK ratio had lower risk
of DU (Table 2): 5 out of 29 (17%) of the SSc patients with
high sCD183/sTWEAK ratio had DU at the time of the
study compared with 33 out of 60 (55%) of those with nor-
mal sCD183/sTWEAK ratio (OR 0.17, 95% CI 0.06, 0.51;
P <0.05). The sCD163/sTWEAK ratio was significantly
greater in patients without DU (5,664 ± 3,158) compared
with patients with DU (3,727 ± 2,687, P = 0.001) (Figure 3).
The sCD163/sTWEAK ratio in patients without DU was
also significantly greater as compared with HC (P =
0.0001) (Figure 3).
Table 2 Comparison of demographic, clinical and laboratory features of SSc patients with high and normal
concentration of sCD163 and high and normal sCD163/sTWEAK ratios.
Characteristica sCD163 sCD163/sTWEAK
High* (n = 13) Normal (n = 76) P-value High* (n = 29) Normal (n = 60) P-value
Age, years 56.08 ± 16.11 57.42 ± 11.67 NS 59.38 ± 12.86 56.18 ± 12.01 NS
Disease duration, years 8.23 ± 6.91 11.66 ± 9.29 NS 11.53 ± 7.81 10.23 ± 9.55 NS
Duration of RP (data available for 54 patients), years 11.46 ± 8.04 9.11 ± 8.58 NS 10.36 ± 7.55 9.32 ± 8.82 NS
DSSc, n/total 5/13 (38.46%) 15/76 (19.74%) NS 10/29 (34.48%) 10/60 (16.67%) 0.055
mRSS (data available for 72 patients) 10.92 ± 9.78 7.95 ± 6.58 NS 12.30 ± 9.68 6.63 ± 4.85 0.0085
ILD, n/total 9/13 (69.23%) 46/76 (60.53%) NS 17/29 (58.6%) 38/60 (63.33%) NS
PH, n/total (data available for 81 patients) 2/13 (15.39%) 2/68 (2.94%) NS 2/29 (6.90%) 2/52 (3.85%) NS
FVC (data available for 75 patients), % of predicted 86.33 ± 19.89 94.56 ± 21.61 NS 95.42 ± 23.40 92.37 ± 20.26 NS
DLCO (data available for 53 patients), % of predicted 74.38 ± 22.94 80.10 ± 30.32 NS 73.16 ± 24.73 82.19 ± 30.97 NS
PASP (data available for 56 patients), mmHg 32.86 ± 12.03 29.23 ± 10.99 NS 29.00 ± 9.25 30.13 ± 12.23 NS
Digital ulcers, n/total 1/13 (7.69%) 37/76 (46.68%) 0.005 5/29 (17%) 33/60 (55%) 0.0006
Anti-topo I, n/total 4/13 (30.77%) 31/76 (40.79%) NS 10/29 (35%) 25/60 (41.67%) NS
ACA, n/total 3/13 (23.08%) 30/76 (39.47%) NS 9/29 45%) 24/60 (40%) NS
ESR (data available for 51 patients), mm/h 28.18 ± 21.05 21.78 ± 19.27 NS 19.64 ± 11.47 24.49 ± 21.93 NS
Arterial hypertension, n/total 2/13 (15.39%) 6/76 (7.90%) NS 3/29 (10.35%) 5/60 (8.33%) NS
CCBs, n/total
Pentoxyphylline, n/total
ACEIs, n/total
Sildenafil, n/total
NSAIDs, n/total
3/13 (23.08%)
5/13 (38.46%)
4/13 (30.77%)
1/13 (7.69%)
3/13 (23.08%)
25/76 (32.90%)
29/76 (38.16%)
8/76 (10.53%)
3/76 (3.95%)
10/76 (13.16%)
NS
NS
NS
NS
NS
8/29 (27.58%)
7/29 (24.14%)
4/29 (13.79%)
1/29 (3.45%)
4/29 (13.79%)
19/60 (31.67%)
26/60 (43.33%)
8/60 (13.33%)
3/60 (5.00%)
9/60 (15.00%)
NS
NS
NS
NS
NS
Because high concentrations of sTWEAK were found in two SSc patients only, no reliable statistical comparisons between SSc patients with high and those with
normal sTWEAK concentration could be performed. Values are given as mean ± SD unless stated otherwise. aData available for 89 patients unless stated
otherwise. *The high concentration of sCD163 and high sCD163/sTWEAK ratio was defined as a value greater than the mean + 2 SD of the value in healthy
controls. sTWEAK, soluble tumour necrosis factor-like weak inducer of apoptosis; NS, not significant (P >0.05); ACA, anticentromere antibodies; ACEIs, angiotensin-
converting enzyme inhibitors; ANA, antinuclear antibodies; CCBs, calcium channel blockers; DLCO, diffusing capacity of the lungs for carbon monoxide; dSSc,
diffuse systemic sclerosis; ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; HRCT, high resolution computed tomography; ILD, scleroderma
interstitial lung disease; mRSS, modified Rodnan skin score; NSAIDs, non-steroidal anti-inflammatory drugs; PASP, pulmonary artery systolic pressure; PH,
pulmonary hypertension; RP, Reynaud’s phenomenon.
Kowal-Bielecka et al. Arthritis Research & Therapy 2013, 15:R69
http://arthritis-research.com/content/15/3/R69
Page 5 of 11
In the whole group of SSc patients, sCD163/sTWEAK
ratio showed a weak correlation with duration of the
disease (R = 0.23, P = 0.03). However, the sCD163/
sTWEAK ratio was not significantly different between
patients with shorter disease duration (4,101 ± 2,650)
compared with patients with longer duration of SSc
(5,271 ± 3,287, P = 0.09).
In multivariate regression analysis, including mRSS,
the presence of DU and disease duration as indepen-
dent values, only mRSS (b coefficient = 0.35, P <0.01)
and the presence of DU (b coefficient = -0.38,
P <0.001) but not disease duration (b coefficient = 0.2,
P >0.05) were independently associated with sCD163/
sTWEAK ratio.
Table 3 Correlations between sCD163, sTWEAK and sCD163/sTWEAK ratio and clinical and laboratory parameters of
patients with systemic sclerosis.
Parameter
(number of subjects)
R Spearman (P-value)
sCD163 sTWEAK sCD163/sTWEAK
Disease duration (89) -0.09
(P >0.05)
-0.32
P = 0.002
0.23
P = 0.03
Duration of Raynaud’s phenomenon (54) 0.14
(P >0.05)
0.11
(P >0.05)
0.03
(P >0.05)
mRSS (82) 0.03
(P >0.05)
-0.08
(P >0.05)
0.13
(P >0.05)
FVC (75) -0.06
(P >0.05)
-0.22
(P >0.05)
0.09
(P >0.05)
DLCO (53) -0.09
(P >0.05)
-0.05
(P >0.05)
-0.02
(P >0.05)
PASP (57) -0.14
(P >0.05)
-0.20
(P >0.05)
0.11
(P >0.05)
ESR (51) 0.15
(P >0.05)
0.07
(P >0.05)
0.04
(P >0.05)
sTWEAK, soluble tumour necrosis factor-like weak inducer of apoptosis; DLCO, diffusing capacity of the lungs for carbon monoxide; ESR, erythrocyte
sedimentation rate; FVC, forced vital capacity; mRSS, modified Rodnan skin score; PASP, pulmonary artery systolic pressure.
Figure 2 Serum concentration of soluble tumour necrosis factor-like weak inducer of apoptosis (sTWEAK) in patients with systemic
sclerosis (SSc) and controls. Concentration of sTWEAK in the sera of all SSc patients (SSc), SSc patients with short-term disease (defined as not
longer than 3 years in diffuse SSc and not longer than 5 years in limited SSc), those with longer disease duration and healthy controls. Closed
circles represent values in individual subjects, bars represent the mean values of the groups, and horizontal lines the appropriate SDs. NS, not
significant.
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No significant association or correlation was found
between the sCD163/sTWEAK ratio and other clinical
or laboratory features of the disease (Tables 2 and 3).
There were no significant differences in sCD163/
sTWEAK ratio between SSc patients receiving different
therapies or between those with and without arterial
hypertension (data not shown), nor any other significant
associations between treatments received by SSc patients
or the presence of arterial hypertension and sCD163/
sTWEAK ratio (Table 2).
Both high concentration of sCD163 and high sCD163/
sTWEAK ratio were associated with lower risk of DU in
SSc patients (Table 2). Analysis of individual SSc
patients revealed that the majority of patients (11 out of
13, 85%) with high sCD163 levels also had high
sCD163/sTWEAK ratio. In the remaining 2 of the 13
SSc patients with high sCD163 levels the sCD163/
sTWEAK ratio was lower than 2 SD above the mean in
the controls (due to relatively high levels of sTWEAK).
Correlation between concentration of sCD163 and
sCD163/sTWEAK ratio in individual SSc patients is
shown in Figure 4.
DU were present in 5 out of 18 (28%) SSc patients
with high sCD163/sTWEAK ratios, but at a normal
sCD163 level, and in none of the SSc patients who had
both high sCD163 levels and sCD163/sTWEAK ratios.
Thus, in our study the presence of both high sCD163
level and high sCD163/sTWEAK ratio was a better pre-
dictor of DU in SSc patients than a high sCD163/
sTWEAK ratio alone.
Discussion
To the best of our knowledge this is the first study eval-
uating relationships between serum sCD163 and
sTWEAK in patients with SSc. We show that the
sCD163/sTWEAK ratio is significantly increased in
patients with scleroderma compared with healthy sub-
jects, and that a high sCD163/sTWEAK ratio is asso-
ciated with greater skin involvement but lower risk of
DU in SSc. Moreover, high serum concentration of
Figure 3 sCD163/soluble tumour necrosis factor-like weak inducer of apoptosis (sTWEAK) in patients with systemic sclerosis (SSc) and
healthy controls. sCD163/sTWEAK ratio in the sera of all SSc patients (SSc), SSc patients without digital ulcers (DU-), SSc patients with digital
ulcers (DU+) and healthy controls. Closed circles represent values in individual subjects, bars represent the mean values of the groups, and
horizontal lines the appropriate SDs. NS, not significant.
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sCD163 was independently associated with fewer DU,
indicating that the processes that lead to elevated secre-
tion of sCD163 and/or sCD163 itself might be involved
in protection against development of DU in SSc.
In the present study the mean serum concentration of
sCD163 in the whole population of SSc patients was sig-
nificantly higher than in HC. Our results are in agree-
ment with two recent reports by Nakayama et al. and
Shimizu et al. In those two studies, which included 43
and 56 Japanese patients with SSc, respectively, serum
concentration of sCD163 was significantly higher in
scleroderma patients compared with the control group
[23,24]. We have confirmed those observations in a
greater population derived from several clinical centres.
CD163 is synthesized exclusively by monocytes/
macrophages and originally expressed as a membrane
protein, which is shed from the cell surface in a process
that is dependent on proteolytic enzymes [4-6]. The
shedding occurs constitutively but can also be induced
by inflammatory stimuli or oxidative stress [36]. Because
of the constant shedding of membrane CD163 it is
assumed that the blood levels of sCD163 may reflect its
overall synthesis by mononuclear phagocytes [37].
Indeed, Higashi-Kuwata et al. reported increased expres-
sion of CD163 on skin macrophages and a subset of
peripheral blood mononuclear cells in SSc patients com-
pared with healthy subjects, which is also in line with
our present findings [38].
Interestingly, elevated serum sCD163 levels in our
study were associated with a significantly lower risk of
DU. Of note, was that previous studies had found an
association between high serum sCD163 levels and
greater frequency of PH or higher pulsatility index,
which is a surrogate marker of kidney arterial injury
[23,24]. However, neither of these two previous reports
separately evaluated relationships between serum
sCD163 levels and active DU [23,24]. Thus, our results
and those of others indicate an association between
CD163 and the involvement of blood vessels in SSc.
The discrepancies between the studies concerning sig-
nificant association with particular forms of vessel invol-
vement might be attributed to the differences in the
clinical profile of patients involved in different studies as
well as to methodological differences in clinical
assessments.
The results of our study do not allow us to make firm
conclusions about the role of CD163 in the pathogenesis
of DU in scleroderma. However, there are several
mechanisms through which CD163 might protect against
development of DU. As a scavenger receptor responsible
for removal of haemoglobin-haptoglobin complexes,
CD163 protects from the toxic effects of free haemoglo-
bin and oxidative stress [39]. This function of CD163
might be of special interest in SSc because microvascular
injury is a constant feature of the disease and might
result in oxidative stress and increased injury to erythro-
cytes, with subsequent release of free haemoglobin [40].
Elevated expression of CD163 has been associated with
triggering anti-inflammatory effects in response to extra-
cellular haemoglobin [9,39]. This phenomenon might
Figure 4 Correlation between concentration of sCD163 and sCD163/soluble tumour necrosis factor-like weak inducer of apoptosis
(sTWEAK) ratio in patients with systemic sclerosis (SSc).
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also be of relevance in SSc because inflammatory reac-
tion, in addition to vascular disease, is believed to be
responsible for increased oxidative stress in scleroderma
patients [40]. It has also been shown that CD163-expres-
sing cells possess pro-angiogenic activity and may stimu-
late formation of new blood vessels through activation of
proliferation of endothelial cells [41]. The latter phenom-
enon might be directly involved in healing of DU and
appears to be an appealing explanation of the association
between high serum sCD163 concentration and absence
of DU in SSc as observed in our study.
As discussed above, it has been shown that CD163
can bind and neutralize TWEAK, a newly identified
member of the TNFa superfamily, which is involved in
the regulation of inflammation, angiogenesis and con-
nective tissue remodelling [16-21]. Although TWEAK is
involved in the regulation of processes that are consid-
ered of key importance in the pathogenesis of SSc, so
far only one study has investigated blood levels of
sTWEAK in SSc [25]. Yanaba et al. found significantly
higher levels of sTWEAK in sera from SSc patients
compared with HC [25]. Unlike Yanaba et al., in the
present study we did not find significant differences in
the serum concentration of sTWEAK between SSc
patients and the control group. The discrepancies
between those two studies can be attributed to differ-
ences in the clinical characteristics of the patients.
Moreover, our present findings are in agreement with
our previous study showing that synthesis of sTWEAK
by peripheral blood mononuclear cells is comparable
between SSc patients and healthy subjects [42].
Consistent with significantly higher sCD163 concentra-
tion in SSc patients and lack of difference in sTWEAK
levels between SSc patients and HC, in our study the
sCD163/sTWEAK ratio was significantly increased in SSc
patients compared with healthy subjects. Both high
sCD163 and sCD163/sTWEAK ratio were associated
with lower risk of DU, suggesting that elevated expres-
sion of CD163 plays a crucial role in that phenomenon,
and the effects are not associated with its ability to neu-
tralize TWEAK. However, in our study high sCD163/
sTWEAK ratio, but not sCD163 alone, was associated
with greater extent of skin fibrosis, indicating that the
CD163-TWEAK interaction might be specifically
involved in the progression of skin disease in SSc The
significance of our findings remains to be established. At
present little is known about the role of CD163 and
TWEAK in the pathogenesis of fibrosis and the available
evidence appears controversial. On one hand, CD163
positive macrophages, which are involved in wound heal-
ing, have been shown to exert profibrotic function [43].
Moreover, in the study by Yanaba et al., serum concen-
tration of sTWEAK inversely correlated with the risk of
ILD, indicating that TWEAK might have a protective
role against the development of fibrosis in SSc patients
[25]. On the other hand, the results of in vitro studies
suggest that inhibition of TWEAK by CD163 might have
a potential anti-fibrotic effect because, as discussed
above, TWEAK can directly activate fibroblast functions
[19-21]. Further studies are therefore required to explain
the role of CD163-TWEAK interactions in the develop-
ment of skin fibrosis in SSc.
Conclusions
In conclusion, we showed that serum concentration of
sCD163 is increased in SSc patients and that high
serum sCD163 level and sCD163/sTWEAK ratio are
associated with lower risk of DU in patients with sclero-
derma. Moreover, the results of our study indicate that
interactions between CD163 and TWEAK might play a
role in the development of skin fibrosis. This appears of
great interest with respect to improvement of the man-
agement of patients with scleroderma. Evaluation of
sCD163 and sCD163/sTWEAK ratio might be helpful in
the assessment of the risk of DU in SSc. Further studies
are required to reveal whether the targeting of the
CD163-TWEAK pathway might be a potential strategy
for treating vascular disease and/or skin fibrosis in SSc.
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